Epimutation and cancer: A new carcinogenic mechanism of Lynch syndrome (Review)

Kouji Banno, Iori Kisu, Megumi Yanokura, Kosuke Tsuji, Kenta Masuda, Arisa Ueki, Yusuke Kobayashi, Wataru Yamagami, Hiroyuki Nomura, Eiichiro Tominaga, Nobuyuki Susumu, Daisuke Aoki

研究成果: Review article査読

40 被引用数 (Scopus)


Epimutation is defined as abnormal transcriptional repression of active genes and/or abnormal activation of usually repressed genes caused by errors in epigenetic gene repression. Epimutation arises in somatic cells and the germline, and constitutional epimutation may also occur. Epimutation is the first step of tumorigenesis and can be a direct cause of carcinogenesis. Cancers associated with epimutation include Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC), chronic lymphocytic leukemia, breast cancer and ovarian cancer. Epimutation has been shown for many tumor suppressor genes, including RB, VHL, hMLH1, APC and BRCA1, in sporadic cancers. Methylation has recently been shown in DNA from normal tissues and peripheral blood in cases of sporadic colorectal cancer and many studies show constitutive epimutation in cancers. Epimutation of DNA mismatch repair (MMR) genes (BRCA1, hMLH1 and hMSH2) involved in development familial cancers has also been found. These results have led to a focus on epimutation as a novel oncogenic mechanism.

ジャーナルInternational journal of oncology
出版ステータスPublished - 2012 9月

ASJC Scopus subject areas

  • 腫瘍学
  • 癌研究


「Epimutation and cancer: A new carcinogenic mechanism of Lynch syndrome (Review)」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。